The Management Board has adopted a revised framework for the EMA’s interaction with patients, consumers and their representative organisations. One of the goals is to incorporate patients’ and consumers’ values and preferences in all evaluation activities, to further ensure the safe and rational use of medicines. Consulting with and listening to patients and consumers also improves plans and policies. The revised framework allows the agency to further build transparency and trust with patients’ and consumers’ communities through their active engagement in EMA activities. The new framework foresees:

• the creation of a pool of disease-specific patient experts to make the process of involvement easier, particularly in product-related activities

• the development of patients’ capacities through training to facilitate their integration in the agency’s work

• the raising of awareness about European regulatory activities to enhance the understanding of regulatory processes.